Obuhangire bwa Agios Pharmaceuticals (AGIO) bwa Sikaati
Agios Pharmaceuticals
AI forecast: AGIO
AI ebandika ekiruho ky'obusobozi bw'omubere gw'ekiseera ekiddako, ekigero ky'omubere gw'ebirungi, n'ekigero ky'omubere gw'omwezi. Okuhinduka kuhakirizwa hakurikira obusobozi bwa nyuma. Bino ni obuhangire bw'obusobozi, si obuhangire bw'okuhanga.
Ebiharwa by'omwaka guhera mu myezi 6 eyita
Premium erikahyora ebyifujiraho by'AI eby'omutengo mu nsi y'omunzi omu, wiiki emu n'omwaka omu ku kizigirwa kino n'ebirala byonna.
Unlock Premium🔒 Ekihugho ky'obuhangire bw'obusobozi
Ekihugho ky'obuhangire bw'obusobozi — buli kihuugho ky'omubere gya nyuma hafi n'obusobozi bwa nyakuri — ni ekigero cya Premium.
Unlock PremiumEbikwata ku Kitongole Kino
Agios Pharmaceuticals, Inc. develops therapeutic agents for the treatment of cancer. The company’s drug development efforts focus on glycolysis, fatty acid metabolism, and autophagy. Agios Pharmaceuticals operates in the United States.
